Cytek Biosciences Inc
NASDAQ:CTKB
Cytek Biosciences Inc
NASDAQ:CTKB
Price:
6.33 USD
-1.4%
Market Closed
Updated:
May 7, 2024
Section:
Relative Value
The Relative Value of one
CTKB
stock under the Base Case scenario is
11.11
USD.
Compared to the current market price of 6.33 USD,
Cytek Biosciences Inc
is
Undervalued by 43%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CTKB
Relative Value
Base Case
11.11
USD
Undervaluation 43%
Valuation Multiples
Multiples Across Competitors
CTKB Competitors Multiples
Cytek Biosciences Inc Competitors
Cytek Biosciences Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Cytek Biosciences Inc
NASDAQ:CTKB
|
827.4m USD | 4.3 | -68.1 | -26 | -20.4 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
222.4B USD | 5.2 | 37.1 | 22.9 | 33.6 | |
| US |
|
Danaher Corp
NYSE:DHR
|
183.8B USD | 4.2 | 22.8 | 16.6 | 20.4 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
41.7B USD | 2.8 | 30.7 | 16.7 | 25.8 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
37.6B CHF | 5.6 | 57.5 | 19.8 | 29 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
55.9T KRW | 15.1 | 65.1 | 34.3 | 49.5 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
41.5B USD | 6.2 | 33.6 | 26.8 | 32.3 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
26.6B USD | 9.1 | 46.9 | 32.5 | 39.5 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.7B USD | 7.1 | 33.9 | 23.7 | 26.3 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
26.2B USD | 3.2 | 38.4 | 17.3 | 26.6 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.2B EUR | 7.1 | 75.3 | 32.4 | 53.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
